Why the study?
Outcomes after percutaneous left atrial appendage occlusion are heterogeneous, and the baseline drivers such as thromboembolic-risk burden, AF chronicity, prior catheter ablation, and frailty are poorly characterized.
Do baseline thromboembolic-risk burden, atrial fibrillation chronicity, prior catheter ablation, and frailty increase the 2-year net adverse clinical composite in adults undergoing percutaneous left atrial appendage occlusion?
Cohort (n=429)
Do baseline thromboembolic-risk burden, atrial fibrillation chronicity, prior catheter ablation, and frailty increase the 2-year net adverse clinical composite in adults undergoing percutaneous left atrial appendage occlusion?
Answers are grounded in this paper and cite their sources.
In patients undergoing percutaneous LAAO, baseline frailty and high CHA2DS2-VASc score (≥5) independently predict 2-year adverse outcomes—driven primarily by death and non-fatal vascular events, respectively—providing a practical risk stratification tool for shared decision-making.
BACKGROUND Outcomes after percutaneous left atrial appendage occlusion (LAAO) are heterogeneous, and the baseline drivers are poorly characterized. OBJECTIVE We examined whether thromboembolic-risk burden, atrial fibrillation (AF) chronicity, prior catheter ablation, and frailty were associated with the 2-year net adverse clinical composite. METHODS We studied 429 consecutive adults undergoing LAAO in a single health system (2018–2023). The primary endpoint was a 2-year composite of all-cause death, ischemic stroke, systemic embolism, or clinically significant bleeding (Bleeding Academic Research Consortium class 3–5). Four baseline phenotype domains were examined jointly in a multivariable Cox model: CHA 2 DS 2 -VASc category (≤4 vs ≥5), AF chronicity (<1 vs ≥1 year), prior catheter ablation within 1 year, and Katz frailty (≤1 vs ≥2 dependent activities of daily living). RESULTS Among 429 patients (median age 77 years; 39.9% women), 122 (28.4%) reached the primary endpoint. After mutual adjustment, both CHA 2 DS 2 -VASc ≥5 (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.23–2.61) and frailty (HR, 1.89; 95% CI, 1.32–2.71) were independently associated with the endpoint; AF chronicity and prior ablation were not. Frailty was the dominant correlate of death (HR, 3.40) and CHA 2 DS 2 -VASc category of the non-fatal vascular events. Two-year cumulative incidence ranged from 15.4% (non-frail, CHA 2 DS 2 -VASc ≤4) to 43.8% (frail, CHA 2 DS 2 -VASc ≥5). CONCLUSIONS After LAAO, thromboembolic-risk burden and frailty were each independently associated with adverse outcomes but acted predominantly on different events. Cross-classifying the two yields an interpretable 2-year risk map that informs post-procedural prognosis and shared decision-making rather than candidacy for LAAO.
No takes yet. Share an insight, caveat, or question.
Alnazeer et al. (2026) conducted a cohort in Atrial fibrillation undergoing percutaneous left atrial appendage occlusion (LAAO) (n=429). Baseline phenotypes (CHA2DS2-VASc ≥5, frailty with ≥2 dependent ADLs, AF chronicity ≥1 year, prior catheter ablation) vs. Lower-risk phenotypes (CHA2DS2-VASc ≤4, non-frail with ≤1 dependent ADL, AF chronicity <1 year, no prior ablation) was evaluated on 2-year composite of all-cause death, ischemic stroke, systemic embolism, or clinically significant bleeding (BARC class 3-5) (HR 1.89, 95% CI 1.32-2.71).
Synapse has enriched 10 related papers. Consider them for comparative context: